Cannara Biotech continues to show resilience despite market fluctuations.
Cannara Biotech Inc. (TSX: LOVE) has had a stable week, closing at C$1.99. This reflects no change over the past week but a notable 10% increase over the last month. The company, which specializes in cannabis production, has made headlines recently with strategic developments aimed at expanding its market presence.
Advertisement
Cannara Biotech Inc.
LOVE.TO
LOVE.TO
Cannara Biotech Inc.
WealthAwesomeMarket cap
$193.61M
P/E
17.8x
52W high
$2.07
52W low
$1.55
1W change
+0.00%
Beta
0.35
Analyst Price Targets
Based on analyst covering LOVE
Wall Street analysts forecast LOVE stock price to rise 70.5% over the next 12 months.
Consensus
BullishBased on avg. target vs last close (formal rating unavailable for Canadian listings)
Avg. Target
C$3.38
+70.5% Upside
Current Price
C$1.98
Last close
Analyst ratings and price targets are updated periodically. Not financial advice.
Wealth Awesome Price Forecast
WA ModelStatistical 90-day price range based on LOVE's historical volatility
30-Day Vol
35.2%
Annualized
90-Day Vol
32.7%
Annualized
Trend (90d)
+50.0%
Annualized drift
90d Mean
C$2.37
Expected price
| Horizon | Expected | 68% Range (1ฯ) |
|---|---|---|
| 30 trading days | C$2.10 | C$1.86 โ C$2.37 |
| 60 trading days | C$2.23 | C$1.88 โ C$2.65 |
| 90 trading days | C$2.37 | C$1.92 โ C$2.92 |
Methodology: Range is calculated using 30-day realized volatility via geometric Brownian motion (log-normal model). 68% band = ยฑ1ฯ, 95% band = ยฑ2ฯ. This is a statistical model, not a prediction. Past volatility does not guarantee future results. Not financial advice.
Advertisement
Investor takeaway: Cannara's recent achievements in revenue growth and strategic partnerships could position the company favorably in the evolving cannabis sector. However, investors should stay informed about market conditions and the company's ongoing developments.
Cannara's stock has increased 10% over the past month.
With a market cap of C$193.6 million and a P/E ratio of 17.82, Cannara Biotech shows promising growth potential while maintaining a healthy profit margin of 9.3%.
Bull case
The company reported record Q3 revenues, indicating strong demand and operational efficiency. Cannara's graduation to the Toronto Stock Exchange enhances its visibility and liquidity, which could attract more investors.
Bear case
Despite these positive developments, Cannara operates in a volatile sector with regulatory uncertainties. The stock's low beta of 0.35 suggests it is less volatile compared to the market, but investors should remain cautious, as small-cap stocks can be sensitive to broader market trends.
Recent Developments
Advertisement
Cannara Biotech has been active in recent months, making several key announcements that could impact its future. Notably, the company revealed a normal course issuer bid on July 22, 2026, allowing it to repurchase up to 1,975,642 common shares. This move aims to enhance shareholder value. Additionally, Cannara reported record Q3 revenues on July 15, 2026, showcasing its ongoing profitability and expanding distribution capabilities. The company also secured a long-term international supply agreement with Curaleaf International Limited, further bolstering its presence in the global market.
Technical Picture
As of the latest close, Cannara Biotech's stock price is C$1.99, which is above its 50-day moving average of C$1.82 and its 200-day moving average of C$1.79, indicating a positive short-term trend. The stock has traded within a 52-week range of C$1.55 to C$2.07, currently sitting at approximately 85% of that range. The stock's beta of 0.35 suggests lower volatility compared to the broader market, which may appeal to risk-averse investors. However, the trading volume of 48,069 shares is slightly below the 20-day average of 50,930, indicating a potential decrease in trading interest.
Insider Activity
No recent insider activity has been reported for Cannara Biotech Inc., which may reflect a stable management outlook or a lack of significant changes in ownership.
Best next step
Keep exploring this topic
If you want to go deeper, these are the most useful follow-up pages and tools for this topic.
Broker comparison
Best trading platforms in Canada
Compare $0-commission brokers before you act on a ticker story.
Safe cash
Best GIC rates in Canada
If the story makes you want to de-risk, compare guaranteed rates next.
HISA roundup
Best high-interest savings accounts
Keep dry powder in a no-fee savings account instead of chequing.
TFSA room
Check TFSA contribution room
Shelter the next contribution before you buy.
Advertisement
Wealth Awesome
Timely coverage of Canadian stocks, earnings, dividends, and market movers for DIY investors. Stories are checked against exchange data and public filings.
View Full Profile โโ Reviewed by Certified Financial Professionals
This content has been reviewed by CFAยฎ charterholders and Certified Financial Planners (CFPยฎ) with over a decade of experience in Canadian financial markets. All information is fact-checked against official Canadian sources and regulations.
Why these credentials matter: CFAยฎ charterholders complete 900+ hours of rigorous study in investment analysis and ethics. CFPยฎ professionals are held to the highest standards of financial planning competency and fiduciary duty in Canada.
โ ๏ธ Professional Disclaimer
This content is for educational purposes only and should not be considered personalized financial advice. While our team brings professional expertise, individual circumstances vary. For personalized guidance, consult with a qualified financial advisor, tax professional, or mortgage specialist.
